The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.40
Bid: 2.32
Ask: 2.54
Change: 0.04 (1.67%)
Spread: 0.22 (9.483%)
Open: 2.41
High: 2.41
Low: 2.34
Prev. Close: 2.39
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: All change for ImmuPharma board as CEO departs

Fri, 30th Jul 2021 15:34

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Friday and not separately reported by Alliance News:

----------

Berkeley Group Holdings PLC - Cobham, England-based housebuilder - Non-Executive Director Alison Nimmo will step down from board at September 3 annual general meeting, having served for 10 years. Nimmo joined the board of St Modwen Properties PLC back in February. She was chief executive of the Crown Estate from 2012 to 2019. The Crown Estate, which manages the Queen's property holdings, is the largest property owner in London's West End. She also held senior roles organising the London 2012 Olympic Games.

----------

ImmuPharma PLC - London-based developer of peptide-based therapeutics for autoimmune diseases - Chief Executive Officer Dimitri Dimitriou steps down immediately "in order to pursue a number of other external opportunities". Chair Tim McCarthy takes over as CEO. ImmuPharma will look for a non-executive chair, and McCarthy will remain chair until it finds one. At the same time, Senior Non-Executive Director Franco di Muzio and Non-Executive Director Stephane Mery also will step down. To replace them, ImmuPharma says it has found new non-executive directors "with direct experience in building a more diverse drug development business together with current public market experience". Sanjeev Pandya is hired as senior independent non-executive director. Pandya was CEO of AIM-listed Advanced Oncotherapy PLC and head of Europe Regulatory & Medical at Reckitt Benckiser Group PLC. Also hires Lisa Baderoon as non-executive director. Baderoon was a partner at financial public-relations firm Buchanan Communications and has been advising ImmuPharma since its AIM float in 2006. It is looking to hire one more non-executive director.

----------

Sylvania Platinum Ltd - South Africa-focused platinum group metals producer - Hires Adrian Reynolds as independent non-executive director, starting on Sunday. Reynolds has more than 40 years' experience in mining and minerals, Sylvania notes, and currently is a director of Resolute Mining Ltd and Mkango Resources Ltd, both London listings.

----------

FD Technologies PLC - Newry, County Down-based financial markets technology, formerly known as First Derivatives - Steve Fisher resigns as non-executive director and will step down at the end of January 2022. Fisher has been appointed to a full-time senior executive role at Salesforce.com Inc, where he previously had worked, FD Technologies explains. The search for a replacement non-executive director has begun.

----------

Record PLC - Windsor, Berkshire-based currency and derivatives manager - Hires Matt Hotson as independent non-executive director, starting Friday. Hotson has worked at Arrow Global Group PLC, RSA Insurance Group PLC, Cable & Wireless Worldwide PLC, and Legal & General Group PLC over a 25-year career.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
28 Jan 2013 16:06

ImmuPharma non-exec reduces stake

Dr Ajay Agrawal, Non-Executive Director of ImmuPharma, sold a stack of shares in the AIM-listed drug company, it was announced Monday. Agrawal traded in 62,169 shares at 57p a time on January 24th, pocketing £35,436 before tax. The deal was announced the same day the group said its key scientific

Read more
28 Jan 2013 12:58

Immupharma reports success of partner's latest Lupus drug trial

Drug development firm ImmuPharma said Monday that its key scientific collaboration partner and the inventor of ImmuPharma's lead compound, Lupuzor, has confirmed the effectiveness of a product known as Lupuzor peptide P140. Partner CNRS released a statement saying that in a clinical trial involvin

Read more
27 Mar 2012 10:27

ImmuPharma's losses grow in 2011

Drug development firm ImmuPharma increased its losses during 2011 but managed to regain the rights to its most important compound. The loss for the year was £3.35m, against the prior year's loss of £1.98m. The loss per share increased from 2.44p in 2010 to 4.12p in 2011. ImmuPharma's lead product

Read more
24 Jan 2012 16:32

SABMiller exec buys a round

The Managing Director of SABMiller's African division bought a round of shares just one day before the drinks giant announced it has signed a definitive transaction agreement with Anadolu Group and Anadolu Efes. The agreement allows the firm to form a strategic alliance between the firm's divisions

Read more
5 Apr 2011 12:01

Immupharma posts wider losses

Drug discovery group Immupharma fell into losses in the year to 31 December, but pointed to progress with its ongoing trials. Pre-tax losses totalled £2m for the year, against a profit of £9.1m the previous year. Revenues fell to just £325,000 from £22.05m. "Early results of our cancer programme

Read more
23 Jun 2010 16:00

UK SMALLCAP ROUNDUP: Mariana Resources Raises GB6.75 Million

Dow Jones smallcap news is on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps MARIANA RESOURCES LTD. (MARL.LN), a gold, silver and copper explorer, Wednesday said it agreed to raise GBP6.75 million in a share sale to fund drilling at i

Read more
23 Jun 2010 07:28

Immupharma Partner Cephalon Starts Phase 2b Trials Recruitment

LONDON (Dow Jones)--Immupharma PLC (IMM.LN), a specialist drug discovery and development company, said Wednesday that Cephalon Inc. (CEPH), its license partner for IPP-201101 (Rigerimod; Lupuzor) has started the recruitment of lupus patients for a Phase IIb trial in the U.S. MAIN FACTS: -Stu

Read more
19 Nov 2009 11:01

Small caps round-up: White Young Green, Beowulf, Angel Biotech...

Engineering consultant White Young Green has traded in line with expectations since the end of June, with conditions varying across its markets. "There remains a lack of confidence and liquidity in many areas in which we trade, but there are also some encouraging signs in respect of opportunities

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.